Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail
Evolus, Inc. (NASDAQ: EOLS) announces the retirement of Chief Financial Officer Lauren Silvernail, effective May 31, 2022, after nearly four years with the company. During her tenure, she significantly contributed to the company's growth, leading efforts in commercial infrastructure and balance sheet restructuring. Silvernail also negotiated a $125 million credit facility to support the company through cash flow breakeven, positioning Evolus for future success. The search for her successor is already underway.
- Successfully negotiated a $125 million credit facility to support operations.
- Transitioned from a development stage organization to a fast-growing commercial business.
- None.
“Lauren has had an incredible impact on this company, and we are grateful for her many contributions to Evolus,” said
Since joining
“It has been a privilege to work alongside such a talented and dedicated group of individuals, and I am excited to embark on this next chapter of my life,” said Silvernail. “I leave knowing the company is in a very strong financial position, with an outstanding leadership team to guide it. I look forward to seeing
About
Forward-Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words “plans,” “expects,” “believes,” “strategy,” “opportunity,” “anticipates,” “outlook,” “designed,” or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words.
Forward-looking statements involve risks and uncertainties that could cause actual results or experiences to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with our ability to address all of our losses, costs, expenses, liabilities and damages resulting from the settlement agreement with Daewoong and our ability to comply with the terms and conditions in the Allergan/Medytox Settlement Agreements, the continued impact of COVID-19 on our business and the economy generally, uncertainties related to customer and consumer adoption of Jeuveau®, the efficiency and operability of our digital platform, competition and market dynamics, and our ability to maintain regulatory approval of Jeuveau® and other risks described in Evolus’ filings with the
Jeuveau® and Nuceiva® are registered trademarks of
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005929/en/
Investor/Media Contact
Vice President, Investor Relations
949-966-1798
david.erickson@evolus.com
Source:
FAQ
What is the latest news on Evolus, Inc. (EOLS)?
Who is replacing the CFO of Evolus, Inc. (EOLS)?
What financial milestone did Evolus achieve recently?
How long did Lauren Silvernail serve as CFO of Evolus, Inc. (EOLS)?